Update on positron emission tomography for imaging of prostate cancer.

Prostate cancer is the most common non-cutaneous malignancy among men in the Western world, and continues to be a major health problem. Imaging has recently become more important in the clinical management of prostate cancer patients, including diagnosis, staging, choice of optimal treatment strategy, treatment follow up and restaging. Positron emission tomography, a functional and molecular imaging technique, has opened a new field in clinical oncological imaging. The most common positron emission tomography radiotracer, ¹⁸ F-fluorodeoxyglucose, has been limited in imaging of prostate cancer. Recently, however, other positron emission tomography tracers, such as ¹¹ C-acetate and ¹¹ C- or ¹⁸ F-choline, have shown promising results. In the present review article, we overview the potential and current use of positron emission tomography or positron emission tomography/computed tomography imaging employing the four most commonly used positron emission tomography radiotracers, ¹⁸ F-fluorodeoxyglucose, ¹¹ C-acetate and ¹¹ C- or ¹⁸ F-choline, for imaging evaluation of prostate cancer. [ABSTRACT FROM AUTHOR]